Efficacy and safety of Lianhua Qingwen in the treatment of patients with moderate COVID-19 infection: A protocol for systematic review and meta analysis

BACKGROUND: : As of June 2020, more than 7 million cases of coronavirus disease (COVID-2019) have been reported worldwide. At present, there is no vaccine or antiviral for the novel coronavirus pneumonia. Lianhua Qingwen (LQ), a Chinese medicine formula, has been authorized by the Chinese government...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Nanyang, Zhang, Tingting, Ma, Lina, Wang, Huican, Cao, Yu, Yang, Yang, Pei, Hui, Li, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437850/
https://www.ncbi.nlm.nih.gov/pubmed/32872017
http://dx.doi.org/10.1097/MD.0000000000021614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437850/
https://www.ncbi.nlm.nih.gov/pubmed/32872017
http://dx.doi.org/10.1097/MD.0000000000021614

Ejemplares similares